Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein

Recruiting now

Conditions studied: HIV Infections

In brief

Antiretroviral therapy (ART) prevents HIV from multiplying. However, if people living with HIV stop taking ART, the virus quickly reappears in their blood due to the random activation of hidden infected cells. These hidden cells contain HIV that is not active and do not produce the virus. These cells are a major challenge in finding a cure for HIV. One of the most promising ways to get rid of these hidden infected cells is by activating them with special drugs called latency-reversing agents (LRAs). This process, known as the "shock-and-kill" strategy, involves waking up the hidden virus ("shock" phase) so that it can be destroyed by the body's immune system or by the virus itself ("kill" phase). Investigators are developing new LRAs that target and activate a viral protein called Tat, which is necessary for the virus to start producing again and for reversing its dormant state.The lead compound, named D10, is the first of its kind to target the Tat protein. This compound has been patented and has shown activity in activating the virus in lab-grown cells. Now, investigators need to test its effectiveness on real target cells from people living with HIV.

Key facts

Study ID

NCT06441123

Run by

University Hospital, Montpellier

People needed

24

Starts

2025-02-10

Expected to finish

2027-02-10

Last updated by the study team

2025-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient aged 18 years or older
• HIV-positive
• On ART (antiretroviral therapy)
• HIV-1 RNA undetectable for more than 12 months
• Nadir CD4 count < 200/µL

You may not qualify if…

• Lack of antiretroviral treatment
• Immunosuppressive treatments
• History of cancer less than 5 years old
• Pregnant or breast-feeding women
• Persons protected by law (under guardianship or curators), persons under court protection
• Participating in another research project with an ongoing exclusion period
• Refusal to participate in research
• Subject not affiliated to a social security scheme, or not benefiting from such a scheme.

Where it is running

• CHU de MONTPELLIER — Montpellier, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.